What is the story about?
What's Happening?
Oncolytics Biotech Inc., a clinical-stage immunotherapy company, has announced its participation in two investor conferences in September 2025. CEO Jared Kelly will meet with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference. The company is advancing its drug pelareorep, which has shown promising results in various cancer studies and has received Fast Track designation from the FDA.
Why It's Important?
Oncolytics Biotech's involvement in these conferences is significant for its strategic growth and development. By engaging with investors, the company aims to secure funding and partnerships to accelerate the development of pelareorep and maximize its commercial impact. The conferences offer a platform to highlight the potential of pelareorep in treating cancers, which could lead to increased investor interest and support.
What's Next?
Oncolytics Biotech will conduct one-on-one meetings with investors during the conferences, providing opportunities for detailed discussions on its research and development strategies. The company may announce new partnerships or funding initiatives following these events, depending on investor feedback and interest.
AI Generated Content
Do you find this article useful?
